PharmiWeb.com - Global Pharma News & Resources
21-Apr-2020

HAEMATO AG: appropriation of profits

HAEMATO AG / Key word(s): Dividend
HAEMATO AG: appropriation of profits

21-Apr-2020 / 18:38 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad-hoc of HAEMATO AG:

The Supervisory Board of HAEMATO AG (ISIN: DE0006190705) approved today's proposal for the appropriation of profits by the Management Board in today's balance sheet meeting. Accordingly, the management of the Annual General Meeting on July 8, 2020 will propose that the retained earnings for the 2019 financial year be carried forward to new account.

 

About HAEMATO:
HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of its business activities is on the growth markets of high-priced specialty pharmaceuticals. The focus is on therapies for cancer, HIV and other chronic diseases.

HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures of the HAEMATO AG share:
Subscribed capital: EUR 22,867,154
Listed class of shares: Bearer ordinary shares
ISIN: DE0006190705
WKN: 619070
Stock exchange code: HAE




Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
ir@haemato.ag

21-Apr-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: HAEMATO AG
Lilienthalstra├če 5c
12529 Sch├Ânefeld
Germany
Phone: +49 (0)30 897 30 86 70
Fax: +49 (0)30 897 30 86 79
E-mail: ir@haemato.ag
Internet: www.haemato.ag
ISIN: DE0006190705
WKN: 619070
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1026705

 
End of Announcement DGAP News Service

Editor Details

Last Updated: 21-Apr-2020